← Back to Search

Local and Systemic Therapy for Cancer

Phase 2
Recruiting
Led By Ethan Ludmir
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; an average of 1 year.
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to see if treating all areas of cancer with radiation therapy or other local treatments, in addition to standard treatments, can help better control the disease compared to just using standard treatments alone.

Who is the study for?
This trial is for individuals with cancer that has spread (metastatic) but only to a limited number of sites and is progressing despite treatment. Participants should be responding well to current systemic therapy except in a few areas.
What is being tested?
The study aims to compare the effectiveness of local consolidation therapy, like radiation or surgery, on all progressing cancer sites versus starting a new systemic treatment regimen.
What are the potential side effects?
Local consolidation therapies may include side effects such as pain, swelling at the treated site, fatigue, and potential damage to nearby tissues or organs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; an average of 1 year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average of 1 year. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety and adverse events (AEs)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: NLST ArmExperimental Treatment1 Intervention
Participants are assigned to Group 1, participants will be treated with next-line systemic therapy. The specific next-line systemic therapy will be determined by your doctor. - If progression occurs (the disease gets worse), participants may cross over to Group 2 and receive LCT.
Group II: LCT ArmExperimental Treatment1 Intervention
Participants are assigned to Group 2, participants will be treated with LCT and then continue on same systemic therapy participants have been receiving followed by the next line systemic of therapy (if applicable). The specific treatments will be determined by your doctor.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,059 Previous Clinical Trials
1,800,468 Total Patients Enrolled
Ethan LudmirPrincipal InvestigatorM.D. Anderson Cancer Center
~133 spots leftby Oct 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top